Stock CHGCY CHUGAI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Chugai Pharmaceutical Co., Ltd. OTC Markets

Equities

CHGCY

US1712691039

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 01:29:59 22/06/2024 am IST 		5-day change 1st Jan Change
16.06 USD -0.06% Intraday chart for Chugai Pharmaceutical Co., Ltd. +2.62% -14.80%
09:00am Japan's Nikkei ends choppy session on stronger note RE
05:27am Japan's Nikkei squeezes out gains in choppy session RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 55,18,359 90,45,924 61,41,311 55,40,406 87,89,053 84,84,884 - -
Enterprise Value (EV) 1 51,85,301 86,67,304 56,69,311 50,51,408 80,50,071 76,46,034 73,99,993 72,33,430
P/E ratio 35 x 42.1 x 20.3 x 14.8 x 27 x 24.6 x 23.2 x 21.9 x
Yield 1.39% 1% 2.03% 2.32% 1.5% 1.64% 1.72% 1.76%
Capitalization / Revenue 8.04 x 11.5 x 6.14 x 4.4 x 7.91 x 7.79 x 7.51 x 7.23 x
EV / Revenue 7.56 x 11 x 5.67 x 4.01 x 7.24 x 7.02 x 6.55 x 6.17 x
EV / EBITDA 22.5 x 26.1 x 12.3 x 8.93 x 17.1 x 15.5 x 14.4 x 13.8 x
EV / FCF 41.5 x 81.2 x 35.3 x 27.7 x 21.6 x 22.8 x 23.4 x 21.6 x
FCF Yield 2.41% 1.23% 2.83% 3.61% 4.63% 4.39% 4.28% 4.64%
Price to Book 6.46 x 9.23 x 5.17 x 3.89 x 5.41 x 4.68 x 4.19 x 3.78 x
Nbr of stocks (in thousands) 16,42,369 16,43,817 16,44,260 16,45,014 16,45,274 16,45,314 - -
Reference price 2 3,360 5,503 3,735 3,368 5,342 5,157 5,157 5,157
Announcement Date 30/01/20 04/02/21 03/02/22 02/02/23 01/02/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 6,86,184 7,86,900 9,99,800 12,59,946 11,11,367 10,89,046 11,30,293 11,72,869
EBITDA 1 2,30,967 3,32,600 4,59,100 5,65,376 4,70,914 4,92,795 5,12,324 5,23,013
EBIT 1 2,10,597 3,01,200 4,21,900 5,33,309 4,39,174 4,68,155 4,96,293 5,24,423
Operating Margin 30.69% 38.28% 42.2% 42.33% 39.52% 42.99% 43.91% 44.71%
Earnings before Tax (EBT) 1 2,07,893 2,98,200 4,19,400 5,31,166 4,43,821 4,70,222 5,01,068 5,29,228
Net income 1 1,57,560 2,14,700 3,03,000 3,74,429 3,25,472 3,45,577 3,66,244 3,88,293
Net margin 22.96% 27.28% 30.31% 29.72% 29.29% 31.73% 32.4% 33.11%
EPS 2 95.95 130.7 184.3 227.6 197.8 209.7 222.2 235.5
Free Cash Flow 1 1,24,900 1,06,723 1,60,699 1,82,312 3,72,635 3,35,326 3,16,836 3,35,310
FCF margin 18.2% 13.56% 16.07% 14.47% 33.53% 30.79% 28.03% 28.59%
FCF Conversion (EBITDA) 54.08% 32.09% 35% 32.25% 79.13% 68.05% 61.84% 64.11%
FCF Conversion (Net income) 79.27% 49.71% 53.04% 48.69% 114.49% 97.03% 86.51% 86.35%
Dividend per Share 2 46.67 55.00 76.00 78.00 80.00 84.67 88.83 90.91
Announcement Date 30/01/20 04/02/21 03/02/22 02/02/23 01/02/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2021 S1 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 S1
Net sales 1 3,65,899 3,68,120 3,90,229 3,22,300 3,60,554 2,35,600 5,96,200 2,25,300 4,38,446 3,12,240 2,67,417 5,79,657 2,57,898 2,73,812 2,36,900 2,80,246 5,00,300 2,74,605 2,95,185 2,50,000 - 5,34,000
EBITDA 1 - - - - - - - - - - - - - 1,31,116 1,07,900 1,36,600 - 1,20,200 1,19,400 - - -
EBIT 1 1,15,545 1,40,629 1,60,679 1,39,100 1,87,007 99,900 2,86,900 96,900 1,49,509 98,296 1,12,614 2,10,910 1,06,688 1,21,576 99,900 1,22,661 2,11,100 1,19,005 1,26,105 1,08,500 - 2,30,900
Operating Margin 31.58% 38.2% 41.18% 43.16% 51.87% 42.4% 48.12% 43.01% 34.1% 31.48% 42.11% 36.39% 41.37% 44.4% 42.17% 43.77% 42.19% 43.34% 42.72% 43.4% - 43.24%
Earnings before Tax (EBT) 1 1,14,113 1,39,565 1,61,256 1,38,400 1,86,206 1,00,700 2,86,900 95,000 1,49,266 99,662 1,13,994 2,13,656 1,07,475 1,22,690 99,900 1,20,150 2,11,350 1,25,850 1,25,650 1,08,800 - 2,31,400
Net income 1 88,306 1,02,293 1,18,137 98,800 1,31,775 72,400 2,04,200 67,800 1,02,429 73,500 83,193 1,56,693 77,573 91,206 74,400 90,770 1,54,400 89,481 91,407 79,300 - 1,69,900
Net margin 24.13% 27.79% 30.27% 30.65% 36.55% 30.73% 34.25% 30.09% 23.36% 23.54% 31.11% 27.03% 30.08% 33.31% 31.41% 32.39% 30.86% 32.59% 30.97% 31.72% - 31.82%
EPS 2 - 62.26 71.86 60.11 80.14 44.00 124.1 41.21 62.29 44.68 50.57 95.25 47.15 55.43 45.22 52.88 92.90 54.37 59.93 48.20 - 103.3
Dividend per Share 2 - 25.00 30.00 - - - 38.00 - - - - 40.00 - 40.00 - 42.00 - - 42.00 - 42.00 -
Announcement Date 30/01/20 27/07/20 26/07/21 03/02/22 25/04/22 21/07/22 21/07/22 24/10/22 02/02/23 27/04/23 27/07/23 27/07/23 24/10/23 01/02/24 24/04/24 - - - - - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 3,33,058 3,78,620 4,72,000 4,88,998 7,38,982 8,38,850 10,84,891 12,51,454
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 1,24,900 1,06,723 1,60,699 1,82,312 3,72,635 3,35,326 3,16,836 3,35,310
ROE (net income / shareholders' equity) 19.6% 23.4% 28% 28.7% 21.3% 19.8% 18.6% 17.3%
ROA (Net income/ Total Assets) 15.9% 26% 30.2% 31.2% 23.3% 18.1% 15.1% 13.6%
Assets 1 9,89,232 8,26,007 10,02,158 12,01,341 13,94,192 19,10,715 24,26,058 28,55,360
Book Value Per Share 2 520.0 596.0 723.0 866.0 988.0 1,101 1,229 1,363
Cash Flow per Share 2 108.0 149.0 203.0 247.0 217.0 236.0 235.0 240.0
Capex 1 53,009 57,040 65,969 61,800 71,948 69,238 71,038 68,600
Capex / Sales 7.73% 7.25% 6.6% 4.9% 6.47% 6.36% 6.28% 5.85%
Announcement Date 30/01/20 04/02/21 03/02/22 02/02/23 01/02/24 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Chugai Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
5,157 JPY
Average target price
5,932 JPY
Spread / Average Target
+15.03%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.63% 796B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.94% 628B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.10% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.95% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.45% 244B
ROCHE HOLDING AG Stock Roche Holding AG
+3.89% 228B
NOVARTIS AG Stock Novartis AG
+12.82% 214B
AMGEN INC. Stock Amgen Inc.
+6.99% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4519 Stock
  4. CHGCY Stock
  5. Financials Chugai Pharmaceutical Co., Ltd.